Safety analysis of home-based enzyme replacement therapy with alglucosidase alfa in Pompe disease; a prospective study

被引：0
|
作者：
Ditters, I. [1 ]
van der Ploeg, A. [1 ]
van der Beek, N. [1 ]
van den Hout, J. [1 ]
Huidekoper, H. [1 ]
机构：
[1] Erasmus MC, Rotterdam, Netherlands
来源：
NEUROMUSCULAR DISORDERS | 2022年 / 32卷
关键词：
D O I：
10.1016/j.nmd.2022.07.146
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
VP.29
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [31] EFFECT SIZE ANALYSIS OF CIPAGLUCOSIDASE ALFA PLUS MIGLUSTAT VERSUS ALGLUCOSIDASE ALFA IN ENZYME REPLACEMENT THERAPY-EXPERIENCED ADULTS WITH LATE-ONSET POMPE DISEASE IN PROPEL
    Dimachkie, Mazen M.
    Bratkovic, Drago
    Byrne, Barry
    Claeys, Kristl G.
    Diaz-Manera, Jordi
    Kishnani, Priya S.
    Kushlaf, Hani
    Roberts, Mark
    Toscano, Antonio
    Castelli, Jeff
    Holdbrook, Fred
    Das, Sheela Sitaraman
    Schoser, Benedikt
    Mozaffar, Tahseen
    MUSCLE & NERVE, 2024, 70 (03) : 524 - 525
  • [32] Strategy to assess the effect of duvoglustat co-administered with alglucosidase alfa infusion on the immune response to enzyme replacement therapy for Pompe disease
    Benjamin, Elfrida R.
    Wu, Xiaoyang
    Della Valle, M. Cecilia
    Sjoberg, Eric
    Sitaraman, Sheela
    Stevens, Anthony
    Gome, Nestor
    Katz, Evan
    Pruthi, Farhana
    Kelley, Jeffry S.
    Wustman, Brandon
    Valenzano, Kenneth J.
    Burne, Barry J.
    Barlow, Carrolee
    Lockhart, David J.
    MOLECULAR GENETICS AND METABOLISM, 2014, 111 (02) : S25 - S25
  • [33] Profile of alglucosidase alfa in the treatment of Pompe disease: safety, efficacy, and patient acceptability
    Schneider, Ilka
    Zierz, Stephan
    RESEARCH AND REPORTS IN ENDOCRINE DISORDERS, 2016, 6 : 1 - 16
  • [34] A Multi-Centre Prospective Study of the Efficacy and Safety of Alglucosidase Alfa in Chinese Patients With Infantile-Onset Pompe Disease
    Zhu, Diqi
    Zhu, Jiacong
    Qiu, Wenjuan
    Wang, Benzhen
    Liu, Lin
    Yu, Xiaodan
    Ou, Zhenheng
    Shan, Guangsong
    Wang, Jian
    Li, Bin
    Chen, Xiaokang
    Liu, Cong
    Li, Zipu
    Fu, Lijun
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [35] Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
    Fiege, Lina
    Duran, Ibrahim
    Marquardt, Thorsten
    PHARMACEUTICALS, 2023, 16 (09)
  • [36] Phase 1 safety and pharmacokinetics of the novel enzyme replacement therapy neoGAA in treatment-naive and alglucosidase alfa-treated late-onset Pompe disease patients
    Ladha, Shafeeq
    Laforet, Pascal
    Mengel, Eugen
    Pestronk, Alan
    Pouget, Jean
    Schoser, Benedikt
    Straub, Volker
    Trivedi, Jaya
    Van Damme, Philip
    Vissing, John
    Young, Peter
    Shafi, Raheel
    Culm-Merdek, Kerry
    Short, Gerard
    Pena, Loren
    MOLECULAR GENETICS AND METABOLISM, 2016, 117 (02) : S117 - S118
  • [37] Enzyme replacement therapy in Pompe disease - An observational study
    Dubrovsky, A.
    Corderi, J.
    Amartino, H.
    Calle, A.
    Montarulli, M.
    CLINICAL THERAPEUTICS, 2008, 30 : S27 - S27
  • [38] Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III
    Sun, Baodong
    Fredrickson, Keri
    Austin, Stephanie
    Tolun, Adviye A.
    Thurberg, Beth L.
    Kraus, William E.
    Bali, Deeksha
    Chen, Yuan-Tsong
    Kishnani, Priya S.
    MOLECULAR GENETICS AND METABOLISM, 2013, 108 (02) : 145 - 147
  • [39] Enzyme Replacement Therapy for Pompe Disease
    Corrado Angelini
    Claudio Semplicini
    Current Neurology and Neuroscience Reports, 2012, 12 : 70 - 75
  • [40] A 4-year follow-up study of 24 patients with late onset Pompe disease treated with alglucosidase alfa enzyme replacement therapy at a single centre
    Stepien, Karolina M.
    Whitby, Jane
    Roberts, Mark
    Sharma, Reena
    MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) : S111 - S111
12345